Beam Therapeutics shared Phase 1/2 data on BEAM-301 for GSDIa; Pfizer partnered with Enodia on Sec61 inhibitors for $500M+; ...
Heidi, an Australian AI health startup, raised $340M from General Catalyst to pursue FDA approval for AI-driven prescribing ...
For decades, Rudy Tanzi has dreamt of a 'little white pill' to prevent Alzheimer’s disease that would be so cheap and so safe ...
BioNTech’s mRNA vaccine BNT113 misses PFS goal in a Phase 2/3 head and neck cancer trial; the study continues toward its overall survival endpoint.
Soufflé Therapeutics raises a $135M Series B led by Juvia Group to push siRNA drugs for FSHD and heart failure into the clinic.
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
Asahi Kasei gets FDA approval for herpes drug Hovilpri for immunocompromised patients, validating its $920M acquisition of ...
A trial testing admilparant in IPF succeeded at the lower 60 mg dose, while the higher 120 mg dose failed. And the GEP-NET ...
AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results